Nuvectis Pharma, Inc.
NVCT
$9.24
$0.819.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.33M | -6.25M | -4.15M | -4.43M | -4.17M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.37M | 1.14M | 1.16M | 1.26M | 1.30M |
| Change in Net Operating Assets | -210.00K | 2.64M | 590.00K | 146.00K | -1.48M |
| Cash from Operations | -4.17M | -2.47M | -2.40M | -3.02M | -4.36M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.80M | 3.95M | 1.51M | 1.73M | 4.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.29M | -124.00K | -50.00K | -55.00K | -153.00K |
| Cash from Financing | 15.51M | 3.83M | 1.46M | 1.67M | 4.70M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.33M | 1.36M | -947.00K | -1.35M | 338.00K |